Display options
Cite
Spinar J, Vítovec J, Spinarová L. Farmakoterapie chronického srdecního selhání po prvních 10 letech 21. století. [Pharmacotherapy of chronic heart failure after the first decade of 21st century]. Vnitr Lek. 2011;57(11):959-65
Spinar, J., Vítovec, J., & Spinarová, L. (2011). Farmakoterapie chronického srdecního selhání po prvních 10 letech 21. století. [Pharmacotherapy of chronic heart failure after the first decade of 21st century]. Vnitrni lekarstvi, 57(11), 959-65.
Spinar, J, et al. "Farmakoterapie chronického srdecního selhání po prvních 10 letech 21. století." [Pharmacotherapy of chronic heart failure after the first decade of 21st century]. Vnitrni lekarstvi vol. 57,11 (2011): 959-65.
Spinar J, Vítovec J, Spinarová L. Farmakoterapie chronického srdecního selhání po prvních 10 letech 21. století. [Pharmacotherapy of chronic heart failure after the first decade of 21st century]. Vnitr Lek. 2011 Nov;57(11):959-65. Czech. PMID: 22165704.
Copy Download .nbib Format: NLM
Share it on

Vnitr Lek. 2011 Nov;57(11):959-65.

[Pharmacotherapy of chronic heart failure after the first decade of 21st century].

Vnitrni lekarstvi

[Article in Czech]
J Spinar, J Vítovec, L Spinarová

Affiliations

  1. Interní kardiologická klinika Lékarsé fakulty MU a FN Brno. [email protected]

PMID: 22165704

Abstract

We provide an overview of the main principles of pharmacological treatment of chronic heart failure. Chronic heart failure is considered to be an epidemic of the 21th century; in the Czech Republic, around 200,000 persons suffer from this condition. Over the last decade, pharmacological and non-pharmacological treatment of heart failure has undergone significant progress and new knowledge arises every year. Generally accepted pharmacological treatment steps include administration of ACE inhibitors, All antagonists (ARB) or beta-blockers, discussions exists on an indication for digoxin, diuretics and lipid-lowering drugs as well as on the importance of ACE-I and ARB. The role of antiarrhythmics is unclear and 2009-2011 have brought about some completely new drug groups-If, channel blockers, factor Xa blockers, thrombin blockers and other agents.

MeSH terms

Publication Types